F Tonelli1, R Valanzano, L Messerini, F Ficari. 1. Department of Clinical Physiopathology, Surgical Unit, University of Florence, Italy. f.tonelli@dfc.unifi.it
Abstract
BACKGROUND AND OBJECTIVES: Ileorectal anastomosis (IRA) is still used in the treatment of familial adenomatous polyposis (FAP). Sulindac appears to induce regression of colorectal adenomas; however, its effects in long-term therapy and in preventing carcinoma remain unclear. METHODS: Fifteen FAP patients treated by IRA received sulindac (200 mg/day) for a mean period of 48.6 +/- 28.7 (range 12-124) months. Number, size, and type of rectal polyps were assessed by endoscopic and histological evaluation every 6 months. RESULTS: Significant regression of polyps was observed in all patients after 6 months (P < 0.02). However, after a mean of 48.6 +/- 28.7 months, both number and size of polyps increased again, showing no statistical difference with baseline values. Minute polyps appeared reddish, while the largest lesions were flat or slightly elevated. Endoscopic polypectomy was necessary in 9 patients and transanal surgical excision in 3. Two patients were submitted to restorative proctectomy because of a large polyp with severe dysplasia and a rectal cancer, respectively. CONCLUSIONS: Sulindac appears to influence the morphological appearance of polyps in FAP patients, inducing apparent regression. However, at a dose of 200 mg, it does not influence the progression of polyps toward a malignant pattern. Copyright 2000 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVES:Ileorectal anastomosis (IRA) is still used in the treatment of familial adenomatous polyposis (FAP). Sulindac appears to induce regression of colorectal adenomas; however, its effects in long-term therapy and in preventing carcinoma remain unclear. METHODS: Fifteen FAPpatients treated by IRA received sulindac (200 mg/day) for a mean period of 48.6 +/- 28.7 (range 12-124) months. Number, size, and type of rectal polyps were assessed by endoscopic and histological evaluation every 6 months. RESULTS: Significant regression of polyps was observed in all patients after 6 months (P < 0.02). However, after a mean of 48.6 +/- 28.7 months, both number and size of polyps increased again, showing no statistical difference with baseline values. Minute polyps appeared reddish, while the largest lesions were flat or slightly elevated. Endoscopic polypectomy was necessary in 9 patients and transanal surgical excision in 3. Two patients were submitted to restorative proctectomy because of a large polyp with severe dysplasia and a rectal cancer, respectively. CONCLUSIONS:Sulindac appears to influence the morphological appearance of polyps in FAPpatients, inducing apparent regression. However, at a dose of 200 mg, it does not influence the progression of polyps toward a malignant pattern. Copyright 2000 Wiley-Liss, Inc.
Authors: Francis M Giardiello; Vincent W Yang; Linda M Hylind; Anne J Krush; Gloria M Petersen; Jill D Trimbath; Steven Piantadosi; Elizabeth Garrett; Deborah E Geiman; Walter Hubbard; G Johan A Offerhaus; Stanley R Hamilton Journal: N Engl J Med Date: 2002-04-04 Impact factor: 91.245
Authors: Photini F S Rice; Kevin G Ehrichs; Mykella S Jones; Hwudarw Chen; Chiu-Hsieh Hsu; Edward R Abril; Raymond B Nagle; David G Besselsen; Jennifer K Barton; Natalia A Ignatenko Journal: Cancer Prev Res (Phila) Date: 2017-11-08
Authors: N Jewel Samadder; Deborah W Neklason; Kenneth M Boucher; Kathryn R Byrne; Priyanka Kanth; Wade Samowitz; David Jones; Sean V Tavtigian; Michelle W Done; Therese Berry; Kory Jasperson; Lisa Pappas; Laurel Smith; Danielle Sample; Rian Davis; Matthew K Topham; Patrick Lynch; Elena Strait; Wendy McKinnon; Randall W Burt; Scott K Kuwada Journal: JAMA Date: 2016 Mar 22-29 Impact factor: 56.272